Nonablative fractional laser improves inflammatory skin disorder appearance

In a new study, a team of researchers—led by Katie Beleznay, MD, of the Department of Dermatology and Skin Science at the University of British Columbia (Vancouver, BC, Canada)—has demonstrated the use of a 1565 nm nonablative fractional laser to treat Lupus miliaris disseminates faciei (LMDF), an inflammatory skin disorder characterized by red-brown papules located on the central face, particularly on and around the eyelids.

While nonablative fractional lasers have been used to effectively treat granulomatous disorders, there is little data on their use for treatment of LMDF, as LDMF is often resistant to treatment.

“Lupus miliaris disseminates faciei (LMDF) is a rare granulomatous disorder that is challenging to treat. We report on the use of a novel 1565 nm nonablative fractionated laser for successful treatment of LMDF which was previously unresponsive to multiple other therapies. This device could be an exciting new tool in the treatment of granulomatous conditions such as LMDF,” states Beleznay.

In the study, a 24-year-old male subject, who had a one-year history with the disorder and did not respond to several topical and oral treatments, showed significant improvement after only one treatment with the nonablative fractional laser therapy. He has since been subsequently treated five times in the past six months and has continued to improve.

Full details of the work appear in the journal Lasers in Surgery and Medicine; for more information, please visit http://dx.doi.org/10.1002/lsm.22295.

-----

Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!